BR9714505A - para o diabetes. - Google Patents

para o diabetes.

Info

Publication number
BR9714505A
BR9714505A BR9714505A BR9714505A BR9714505A BR 9714505 A BR9714505 A BR 9714505A BR 9714505 A BR9714505 A BR 9714505A BR 9714505 A BR9714505 A BR 9714505A BR 9714505 A BR9714505 A BR 9714505A
Authority
BR
Brazil
Prior art keywords
glitazone
diabetes
sulphonylureiidiabetic
sulfonylurea
improvement
Prior art date
Application number
BR9714505A
Other languages
English (en)
Portuguese (pt)
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9714505A publication Critical patent/BR9714505A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9714505A 1997-02-19 1997-12-01 para o diabetes. BR9714505A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (1)

Publication Number Publication Date
BR9714505A true BR9714505A (pt) 2000-03-21

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714505A BR9714505A (pt) 1997-02-19 1997-12-01 para o diabetes.

Country Status (29)

Country Link
US (2) US5859037A (https=)
EP (1) EP0957923A1 (https=)
JP (1) JP2001512478A (https=)
KR (1) KR20000071179A (https=)
CN (1) CN1244801A (https=)
AR (1) AR011829A1 (https=)
AU (1) AU741215B2 (https=)
BG (1) BG103671A (https=)
BR (1) BR9714505A (https=)
CA (1) CA2272478A1 (https=)
CZ (1) CZ289299A3 (https=)
EA (1) EA199900725A1 (https=)
EE (1) EE9900345A (https=)
GT (1) GT199800037A (https=)
HN (1) HN1997000167A (https=)
HU (1) HUP0001528A3 (https=)
IL (1) IL130027A (https=)
IS (1) IS5058A (https=)
NO (1) NO993982D0 (https=)
NZ (1) NZ336002A (https=)
PA (1) PA8447401A1 (https=)
PE (1) PE74399A1 (https=)
PL (1) PL335166A1 (https=)
SK (1) SK111899A3 (https=)
SV (1) SV1998000010A (https=)
TR (1) TR199902033T2 (https=)
UY (1) UY24893A1 (https=)
WO (1) WO1998036755A1 (https=)
ZA (1) ZA981343B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
KR20060105005A (ko) * 1997-06-18 2006-10-09 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
BR9810142A (pt) * 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
PL352756A1 (en) * 1998-12-24 2003-09-08 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
DE60035163T2 (de) * 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2003272504A1 (en) 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
CA2622069A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
ES2638977T3 (es) 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
BR122021011394B1 (pt) * 2008-12-04 2021-09-28 Chongxi Yu Composição de alta penetração de um fármaco principal, e uso de uma hpc
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
CN102655866B (zh) * 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US9241952B2 (en) 2010-05-24 2016-01-26 Ozstar Therapeutics Pty Ltd Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
CN103582463B (zh) 2011-01-19 2018-02-13 弗拉克泰尔实验室公司 用于组织处理的装置与方法
KR102104384B1 (ko) 2011-11-23 2020-04-27 오즈스타 테라피우틱스 피티와이 엘티디 개선된 상승작용성 항-당뇨병성 조성물
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
AU2013226062B2 (en) 2012-02-27 2017-10-19 Fractyl Health, Inc. Heat ablation systems, devices and methods for the treatment of tissue
EP2838598B1 (en) 2012-04-19 2020-01-15 Fractyl Laboratories, Inc. Tissue expansion devices
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
EP3071286B1 (en) 2013-11-22 2024-01-03 Fractyl Health, Inc. Systems for the creation of a therapeutic restriction in the gastrointestinal tract
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
EP4090282A4 (en) 2020-01-15 2024-02-21 Fractyl Health, Inc. AUTOMATIC FABRIC TREATMENT DEVICES, SYSTEMS AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
PE74399A1 (es) 1999-08-20
EA199900725A1 (ru) 2000-04-24
SK111899A3 (en) 2000-09-12
AR011829A1 (es) 2000-09-13
AU5590898A (en) 1998-09-09
HN1997000167A (es) 1999-02-09
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
EE9900345A (et) 2000-02-15
IS5058A (is) 1999-05-27
TR199902033T2 (xx) 2000-02-21
CZ289299A3 (cs) 1999-11-17
ZA981343B (en) 1998-11-16
CA2272478A1 (en) 1998-08-27
US5972973A (en) 1999-10-26
IL130027A0 (en) 2000-02-29
UY24893A1 (es) 1998-07-10
HUP0001528A3 (en) 2000-12-28
AU741215B2 (en) 2001-11-29
PA8447401A1 (es) 2001-12-14
JP2001512478A (ja) 2001-08-21
NZ336002A (en) 2002-03-28
WO1998036755A1 (en) 1998-08-27
PL335166A1 (en) 2000-04-10
SV1998000010A (es) 1999-02-02
NO993982L (no) 1999-08-18
IL130027A (en) 2005-09-25
EP0957923A1 (en) 1999-11-24
US5859037A (en) 1999-01-12
KR20000071179A (ko) 2000-11-25
NO993982D0 (no) 1999-08-18
BG103671A (en) 2000-04-28
CN1244801A (zh) 2000-02-16

Similar Documents

Publication Publication Date Title
BR9714505A (pt) para o diabetes.
PA8484901A1 (es) Combinaciones para la diabetes
IT1293404B1 (it) Cartuccia di inchiostro e meccanismo di caricamento per tale cartuccia di inchiostro.
DK0533781T3 (da) 3-aryl-2-hydroxypropionsyrederivater og -analoger som hypoglykæmiske midler
ES2072452T3 (es) Medios cosmeticos desodorizantes.
DK0782855T3 (da) Nimesulid til ekstern anvendelse
BR9303868A (pt) Compostos composicao uso e processo para estabilizacao de um material organico
DK1011673T3 (da) Hidtil ukendt metode til behandling af nidom
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
NO20001142D0 (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
NO20001139D0 (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
ATE295423T1 (de) Phosphodiesterase 8
CO5021192A1 (es) Metodo cosmetico para tratar cabello coloreado
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
NO921256D0 (no) Aminosyre-beta-lyaseenzyminhibitor som deodoranter
BR9402818A (pt) Composto, composição, processo para estabilização de um material orgânico e uso
FI852610L (fi) Dihydropyridiner innehaollande fasta laekemedelsprodukter och foerfarande foer deras framstaellning.
BR9906057A (pt) Método de fabricação de composição para uso no controle de moscas frutiferas
FI881910L (fi) Underlag i synnerhet foer personer som saknar roerelsefoermaoga.
BR9807691B1 (pt) composição aerossol cosmética antiperspirante, e, uso não-terapêutico de uma composição aerossol antiperspirante.
NO913502D0 (no) Kompositt for anvendelse som hoeyenergi-sprengstoff eller drivmiddel.
BR9808216B1 (pt) composição farmacêutica ou cosmética compreendendo retinóide com melibiose, uso da mesma e método para o tratamento cosmético de alterações associadas com o envelhecimento da pele e/ou o exoesqueleto.
EP0401379A4 (en) Stabilized composition of interleukin-1-g(b)
ATE105291T1 (de) Spiro-isochinolin-pyrrolidin-tetrone und analoge davon, verwendbar als aldosereduktaseinhibitoren.
ATE248781T1 (de) Glaspulver und dessen verwendung

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO APRESENTA REIVINDICACOES QUE NAO ATENDEM AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGO 8O COMBINADO COM O ARTIGO 13 DA LEI 9279/96 )